These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 16930573)

  • 41. Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route.
    Tu CF; Lin CC; Chen MC; Ko TM; Lin CM; Wang YC; Lai MD
    Vaccine; 2007 Jan; 25(4):719-28. PubMed ID: 16962215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
    Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL
    Am J Pathol; 2005 Apr; 166(4):1205-16. PubMed ID: 15793299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
    Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
    Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice.
    Sfondrini L; Rodolfo M; Singh M; Colombo MP; Colnaghi MI; Ménard S; Balsari A
    Cancer Res; 2000 Jul; 60(14):3777-81. PubMed ID: 10919650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice.
    Wei WZ; Jacob JB; Zielinski JF; Flynn JC; Shim KD; Alsharabi G; Giraldo AA; Kong YC
    Cancer Res; 2005 Sep; 65(18):8471-8. PubMed ID: 16166327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
    Kim JH; Majumder N; Lin H; Chen J; Falo LD; You Z
    Mol Ther; 2005 Jun; 11(6):941-9. PubMed ID: 15922965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.
    Jacob JB; Kong YC; Nalbantoglu I; Snower DP; Wei WZ
    J Immunol; 2009 May; 182(9):5873-81. PubMed ID: 19380836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
    Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
    Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.
    Whittington PJ; Radkevich-Brown O; Jacob JB; Jones RF; Weise AM; Wei WZ
    Cancer Immunol Immunother; 2009 May; 58(5):759-67. PubMed ID: 18836716
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
    Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
    Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys.
    Ko HJ; Kim YJ; Kim YS; Kim JM; Ho SH; Jeong JG; Oh SM; Chae JA; Kim CY; Lee PS; Kang CY
    Gene Ther; 2008 Oct; 15(20):1351-60. PubMed ID: 18480847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.
    De Giovanni C; Nicoletti G; Landuzzi L; Croci S; Palladini A; Antognoli A; Murgo A; Ianzano ML; Grosso V; Stivani V; Iezzi M; Musiani P; Nanni P; Lollini PL
    Vaccine; 2009 Mar; 27(14):2065-9. PubMed ID: 19428831
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
    J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS; Morrison SL; Penichet ML
    Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
    Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.
    Croci S; Recktenwald CV; Lichtenfels R; Nicoletti G; Dressler SP; De Giovanni C; Astolfi A; Palladini A; Shin-ya K; Landuzzi L; Nanni P; Lollini PL; Seliger B
    Proteomics; 2010 Nov; 10(21):3835-53. PubMed ID: 20957756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
    Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
    Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110.
    Manjili MH; Henderson R; Wang XY; Chen X; Li Y; Repasky E; Kazim L; Subjeck JR
    Cancer Res; 2002 Mar; 62(6):1737-42. PubMed ID: 11912148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.